Camilla Soenderby

Camilla Soenderby is an accomplished industry leader with extensive experience in the biotechnology and pharmaceutical sectors. Currently, Camilla serves on the Board of Directors for BB Biotech and Abivax, focusing on investments and innovative therapeutics, respectively. Camilla is also a member of the Novo Holdings Advisory Group and the board of Affibody AB and F2G, contributing expertise in life sciences investments and biopharmaceutical development. Previous roles include Corporate Officer at Takeda and SVP at Shire, where Camilla led product strategy initiatives. Camilla has provided advisory services for EQT Partners and has held significant leadership positions at Roche. Educational credentials include degrees from the University of St. Gallen and Københavns Universitet.